Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SES: T14.SI) Stock Competitors & Peer Comparison
See T14.SI's competitors and their performance on the SES and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for T14.SI and its SES peers.
Stock Comparison
iX Biopharma Ltd. (SES: 42C.SI)
T14.SI vs 42C.SI Comparison August 2026
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SES: T14.SI) plays a significant role within the Healthcare sector. Its performance on the SES reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, T14.SI stands at 3.3B. In comparison, 42C.SI has a market cap of 453.7M. Regarding current trading prices, T14.SI is priced at SGD 2.54 on the SES, while 42C.SI trades at SGD 0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
T14.SI currently has a P/E ratio of 6.35, whereas 42C.SI's P/E ratio is -35.26. In terms of profitability, T14.SI's ROE is +0.11%, compared to 42C.SI's ROE of -2.14%. Regarding short-term risk, T14.SI is less volatile compared to 42C.SI. This indicates lower risk in terms of short-term price fluctuations for T14.SI.Check 42C.SI's competition here